Treatment landscape

What is the treatment landscape?

The treatment landscape is a structured overview of how a disease or condition is currently treated and how care is likely to change. It covers standards of care, approved medicines, emerging therapies, therapeutic classes, non-drug interventions, clinical practice, treatment guidelines and areas of unmet need.

It should show where treatments are used in the patient pathway, including treatment sequencing, eligible populations, lines of therapy and reasons for switching or stopping. Because practice differs by geography, care setting and patient group, the scope and date of the landscape should always be stated. It evolves as evidence, competition, clinical practice and policy change.

Why does the treatment landscape matter in clinical and access strategy?

A treatment landscape gives clinical, medical and market access teams a shared view of the context in which a medicine will be assessed and used. It informs target product profiles, trial population and comparator choices, evidence planning, product positioning and value messages.

For access teams, it helps identify the therapies and care pathways against which payers and assessment bodies may judge relative benefit, cost and place in treatment. For clinical teams, it highlights changing standards of care that could affect study relevance, recruitment or interpretation. An incomplete or outdated view can lead to unsuitable comparators, weak differentiation claims or evidence that no longer answers decision-makers’ questions.

How is a treatment landscape produced in practice?

The work starts with a defined disease area, patient population, geography, care setting and time horizon. Teams then gather and organise evidence from sources appropriate to the decision being supported. A practical process includes:

• Mapping the patient pathway from diagnosis through treatment, monitoring, switching and later care.
• Recording approved therapies, therapeutic classes, indications, restrictions and common treatment sequences.
• Reviewing guidelines, prescribing practice and relevant reimbursement or health technology assessment decisions.
• Identifying pipeline assets, trial readouts and potential changes to future standards of care.
• Comparing efficacy, safety, administration, monitoring, service burden and other factors that influence treatment choice.
• Validating assumptions with medical, clinical, access and local market experts.

The output may be a narrative review, structured matrix, treatment algorithm or visual pathway. Sources, assumptions and evidence gaps should remain visible so users can distinguish established practice from expert interpretation or anticipated change.

How is a treatment landscape different from a market landscape?

A treatment landscape concentrates on clinical management: what treatments exist, where they sit in the pathway, how clinicians use them and what needs remain unresolved. A market landscape is broader and may include market size, sales, competitors, customer segments, commercial performance and forecasts.

The two overlap because clinical practice affects market opportunity, while access conditions and competitor activity affect uptake. They should not be treated as interchangeable. A treatment landscape can support commercial analysis, but its primary organising logic is the patient pathway and treatment decision.

Who owns the treatment landscape, and how should it be maintained?

Ownership is usually cross-functional rather than confined to one team. Medical affairs may lead the clinical narrative, clinical development may contribute pipeline and study context, and access teams may add payer restrictions and assessment outcomes. Local affiliates are important where guidelines, funding and practice vary between countries or care settings.

A useful landscape has named ownership, traceable sources and a clear update process. It should be reviewed when material evidence, approvals, guideline recommendations, competitor events or policy decisions change the likely pathway. Common failures include presenting formal guidelines as if they fully represent practice, mixing evidence from incompatible populations, overlooking non-drug care and describing pipeline therapies as though their future role were settled.

How does a treatment landscape relate to adjacent evidence and strategy terms?

The treatment landscape describes the available and emerging options and their place in care. An unmet-need assessment examines the problems that current care does not adequately solve. An evidence generation programme plans the studies and analyses needed to address those gaps, while access and commercial strategies decide how a particular medicine should be positioned within the resulting clinical and decision-making context.